A phase 1b, multicenter, dose-escalation study of subasumstat (TAK-981) in combination with pembrolizumab in patients (pts) with advanced solid tumors.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Sanjay Goel, Susanna Varkey Ulahannan, Anthony J. Olszanski, Patricia LoRusso, Rachel E. Sanborn, Sunil Sharma, Leisha A. Emens, Matthew Reilley, Victor Priego, Shuli Li, Bingxia Wang, Lixian Dong, Kris Sachsenmeier, John Gibbs, Robert Gharavi, Alonzo Martinez, Igor Proscurshim, Robert J. Fram, Alejandro Gomez-Pinillos, Drew W. Rasco
Institutions: Rutgers, The State University of New Jersey, OU Health Stephenson Cancer Center, Fox Chase Cancer Center, Yale Cancer Center, Providence Portland Medical Center, HonorHealth, UPMC Hillman Cancer Center, University of Virginia Cancer Center, Center for Cancers and Blood Disorders, South Texas Accelerated Research Therapeutics
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4286297044